A summary of recent news and announcements from Milton Park-based companies:
- Immunocore reports 32% year-on-year revenue growth in Q2 2025 results
- LIO (formerly Oxehealth) rebrands and launches next-generation mental health platform
- Physiomics secures follow-on contract for Virtual Tumour™ platform
- Recursion advances AI-driven drug discovery with progress update
- Summit Therapeutics’ ivonescimab selected for WCLC Presidential Symposium
Immunocore reports 32% year-on-year revenue growth in Q2 2025 results
Immunocore has announced robust financial results for the second quarter of 2025, delivering strong revenue growth as it expands access to its groundbreaking cancer treatment KIMMTRAK.
The company, which pioneers transformative immunomodulating medicines (which activate the immune system’s T cells) for cancer, infectious diseases and autoimmune diseases, reported 32% year-on-year revenue growth for the first half of 2025.
This growth reflects its successful efforts to expand KIMMTRAK availability in the US and internationally, which treats adults with a rare and aggressive form of eye cancer.
Bahija Jallal, Chief Executive Officer of Immunocore, commented: “We are delighted to announce robust revenue for the first half of 2025, a 32% year-over-year increase. This is testament to our steadfast dedication to expanding access to KIMMTRAK in the US and across the globe.
“We are also advancing our Phase 1/2 trials in oncology and infectious diseases and preparing for the clinical trial applications for our autoimmune candidates, further underscoring the depth and diversity of our platform.”
LIO (formerly Oxehealth) rebrands and launches next-generation mental health platform
The Bee House-based digital mental health innovation leader Oxehealth has relaunched as LIO, and has unveiled a next-generation operating platform designed to transform inpatient mental health care across hospitals. The company, which has spent over 15 years collaborating closely with NHS mental health trusts, developed the new platform to enable safer, more personalised care.
Already trusted by half of NHS England’s mental health providers through its predecessor Oxevision, LIO brings together ambient monitoring, digital observations and management insights in one, unified platform.
The solution features adaptive monitoring modes that support personalised care, advanced compliance reporting, and digital observations with smart scheduling and missed-observation alerts.
Todd Haedrich, CEO of LIO, said: “LIO reflects everything we’ve learned from working shoulder-to-shoulder with our partners. It is a fully integrated, whole-hospital solution, purpose-built for the complex realities of inpatient mental health, with powerful new capabilities that help providers deliver consistently high standards of compassionate, patient-centred care.”
LIO will begin rolling out in the UK from 2026, with enterprise-level analytics tools planned to help provider networks measure safety performance across sites and improve staff efficiency at scale.
Physiomics secures follow-on contract for Virtual Tumour™ platform
Mathematical modelling and data science company Physiomics has been awarded a second contract by a UK-based biotech client. It follows the successful completion of a previous project that demonstrates the growing impact of model-informed approaches in drug development.
Physiomics, which specialises in supporting the development of new therapeutics and personalised medicine solutions, will update a model previously developed for the AI-driven drug development client. The update will incorporate clinical data from an ongoing Phase one study and be used to support critical decisions regarding future clinical dosing strategy.
The £38,000 project will use Physiomics’ proprietary Virtual Tumour platform. It is expected to be completed over the next two months and represents continued momentum in the company’s Modelling and Simulation division.
Dr Peter Sargent, CEO of Physiomics, said: “We’re delighted to be working again with this valued client and to continue supporting the development of their oncology programme. This follow-on project provides a strong opportunity for our Virtual Tumour platform to help guide important clinical decisions and demonstrates the growing impact of model-informed approaches in dose optimisation decisions.”
Recursion advances AI-driven drug discovery with Q2 progress update
AI-powered drug discovery company Recursion has reported its second quarter results, which show continued progress in its advanced platform capabilities to accelerate pharmaceutical development and partnerships.
The Milton Park and US-based company highlighted how its platform allows both drug discovery and development while providing insights on patient populations that would be challenging to identify through traditional methods. During the quarter, Recursion achieved its fourth partnered discovery milestone with pharmaceutical giant Sanofi, demonstrating tangible momentum across their joint pipeline.
Beyond Sanofi, Recursion has maintained strategic discovery partnerships with major pharmaceutical companies including Roche and Genentech, Bayer and Merck KGaA.
Chris Gibson, CEO of Recursion, commented: “The power of our platform not only allows us to discover and develop potential new medicines, but also gives us insights on patient populations to target that would be challenging using traditional methods. State of the art platform capabilities helped us drive our fourth partnered discovery milestone with Sanofi this quarter, reflecting tangible momentum across our joint pipeline.”
Summit Therapeutics’ ivonescimab selected for WCLC Presidential Symposium
Biopharmaceutical company Summit Therapeutics has announced data from its Phase III HARMONi trial will be presented at the prestigious Presidential Symposium at the 2025 World Conference on Lung Cancer, marking the second consecutive year the company has been featured in the leading forum.
The company’s investigational bispecific antibody, ivonescimab, showed statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated non-small cell lung cancer.
The company is focused on improving patient outcomes for serious unmet medical needs.
The HARMONi trial represents a breakthrough in treating patients who have progressed after treatment with 3rd generation EGFR tyrosine kinase inhibitors, addressing a significant unmet medical need in oncology. The trial results will be presented by Professor Jonathan Goldman from UCLA at the Barcelona conference on September 7, 2025.
The selection for the WCLC Presidential Symposium represents recognition of the clinical significance of Summit’s work in developing potential first-in-class treatments for challenging cancer populations.
Sign up to our newsletter
Subscribe
